Nanobix

About

Nanobix, founded in 2018 in Basel, Switzerland, is an innovative biotechnology company developing next-generation nanopore-based biosensors for rapid point-of-care diagnostics. Based in Basel, a global hub for pharmaceutical and biotechnology innovation, Nanobix leverages cutting-edge nanotechnology to create diagnostic devices that can detect disease biomarkers quickly and accurately outside traditional laboratory settings. The company's nanopore biosensor platform utilizes nanoscale pores—typically 1-10 nanometers in diameter—embedded in thin membranes as highly sensitive molecular detectors. When target molecules pass through or interact with these nanopores under an applied electrical field, they produce characteristic changes in ionic current that serve as molecular fingerprints for identification and quantification. This single-molecule detection approach offers exceptional sensitivity and specificity, enabling detection of biomarkers at clinically relevant concentrations from small sample volumes. Nanobix's technology addresses critical needs in point-of-care diagnostics, where rapid results can significantly impact patient management and treatment decisions. The nanopore platform is particularly well-suited for detecting nucleic acids, proteins, and other biomolecules associated with infectious diseases, cancer, and cardiovascular conditions. Unlike conventional diagnostic methods requiring extensive sample preparation and laboratory infrastructure, nanopore sensors can potentially deliver results in minutes from raw or minimally processed samples. The company has secured over $5 million in funding to advance its platform through development and validation stages. Switzerland's strong scientific ecosystem, with world-class universities and research institutions, provides Nanobix with access to expertise in nanofabrication, biosensor development, and clinical diagnostics. The company's work represents an important advancement in translating nanopore technology, originally developed for DNA sequencing, into broader diagnostic applications. As healthcare systems increasingly emphasize decentralized testing and rapid diagnosis, Nanobix's nanopore biosensors could play a significant role in bringing laboratory-quality diagnostics to point-of-care settings worldwide.